The human cytomegalovirus is the leading cause of non-genetic hearing loss in babies. (1)
ROCHESTER, NY, UNITED STATES, November 18, 2015 /EINPresswire.com/ —
Research shows that the human cytomegalovirus (CMV) can cause hearing loss in babies. In fact, “CMV is the most frequently occurring congenital viral infection in babies in the United States … It has been reported that this virus causes approximately one-third of all pediatric hearing loss.” (1) Additionally, the American Academy of Pediatrics (AAP) notes that “Approximately 30- 50% of children with clinically apparent disease (symptomatic) and 8-12% of children without clinically apparent (asymptomatic) congenital CMV infection will develop SNHL (Sensorineural Hearing Loss).” (2)
Click to learn more about CMV symptoms.
It should be noted that “less than half of the hearing loss due to CMV infection is present at birth. Other CMV infected children may go on to develop late onset loss during the preschool and early school years. Approximately 33 to 50% of SNHL due to congenital CMV infection is late onset loss.” (2)
Are there treatments available against the cytomegalovirus?
Yes there are. “Several drugs are approved for the treatment of CMV infections in immunocompromised individuals. These drugs include ganciclovir, its oral prodrug valganciclovir, cidofovir, foscavir and fomivirsen. However, the use of these drugs in immunocompetent individuals is limited by their toxicity, poor oral bioavailability, modest efficacy, and the development of drug resistance.” (3) There are also two natural CMV remedies with a clinically proven formula.
The bottom line?
Research shows that CMV in babies can cause hearing loss even if not present at birth most cases in fact show at later ages such as preschool or the early school years.
References:
(1) “Frequently Asked Questions about Cytomegalovirus (CMV)” – “What is the connection between CMV and hearing loss?” – cmvcouncil.org
(2) Fowler, K. “Congenital Cytomegalovirus (CMV) Infection & Hearing Loss” – https://www.aap.org/en-us/advocacy-and-policy/aap-health-initiatives/PEHDIC/Documents/CMV.pdf
(3) Polansky H, Itzkovitz E. Gene-Eden-VIR Is Antiviral: Results of a Post Marketing Clinical Study. Pharmacology & Pharmacy, 2013, 4, 1-8
http://www.scirp.org/journal/PaperInformation.aspx?PaperID=36101#.VCfZypSSz90
Greg Bennett
CBCD
585-250-9999
email us here